Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE

Daniele Santini,Saverio Cinieri,Donatello Gasparro,Roberto Bordonaro, Pamela Francesca Guglielmini,Vincenzo Emanuele Chiuri,Rolando M D'Angelillo,Giovanni Luca Ceresoli,Daniele Fagnani, Mirko Acquati,Manlio Mencoboni,Gaetano Lanzetta,Donata Sartori,Paolo Carlini, Fabiana Panebianco,Patrizia Beccaglia,Giuseppe Procopio

Journal of Bone Oncology（2021）

引用 5|浏览70

暂无评分

摘要

•Bone remodeling is disrupted in metastatic disease, affecting > 70% of mCRPC men.•In metastatic disease, abnormal levels of specific BTMs are released.•We prospectively measured four BTMs markers in chemotherapy-naïve mCRPC men on AAP therapy.•AAP seems to act on the microenvironment of metastatic but not of normal bone.•This action likely contributes to the antitumoral activity of AAP.

查看译文

关键词

Abiraterone acetate,Bone alkaline phosphatase,Bone targeting therapy,Bone turnover biomarkers,C-terminal telopeptide,mCRPC

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要